Drug Delivery by Tattooing to Treat Cutaneous Leishmaniasis by Shio, Marina Temi et al.
Supplementary Information
DRUG DELIVERY BY TATTOOING TO TREAT 
CUTANEOUS LEISHMANIASIS
Marina Temi Shio, Marilene Paquet, Caroline Martel, Tom Bosschaerts, 
Stef Stienstra, Martin Olivier and Anny Fortin*
*Corresponding author: anny.fortin@mcgill.ca
a b
0
2
4
6
8
10
60
70
80
90
100
med 1 3 9
OlPC-lipo (µM)
9 100
LPS
L.mexicana
Leishmania - + --+++
L. major
N
O
2-
( µ
M
)
0
50
100
150
200
250
med 1 3 9
OlPC-lipo (µM)
9 200
HZ
Leishmania - + --+++
L.major
L.mexicana
R
LU
 
(x
10
3 )
Figure S1
Supplementary Figure 1. OlPC does not induce NO or ROS production in Leishmania-
infected macrophage-derived cell lines. L. mexicana or L. major–infected B10R cells were
treated with medium (med) or with indicated concentrations of OlPC liposomes (OlPC-lipo)
alongside with 100 ng/ml LPS or 200 µg/ml hemozoin (HZ) as positive controls. After 24 h
the supernatants were collected to determine the concentrations of (a) nitrite by Griess assay
or (b) ROS by exposure to a cell permeable DCFH-DA for different times for 3 hrs. Data are
expressed as mean + SEM, n=2 - 4 experiments.
